News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

03 Jul, 2020, 07:30 BST IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product...


08 Jun, 2020, 21:00 BST CSL Behring to Acquire Biotech Company Vitaeris

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused ...


08 Jun, 2020, 07:00 BST CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...


24 Jan, 2020, 12:10 GMT Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 ...


13 Mar, 2018, 17:22 GMT CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines

In a keynote address on patients' access to medicines at the eyeforpharma Barcelona summit, CSL Chief Executive Officer and Managing Director Paul...


31 Mar, 2017, 15:00 BST Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish a...


10 Dec, 2015, 09:00 GMT CSL Behring Expands Operations to Russia

Global biotherapeutics leader CSL Behring announced today its latest geographic expansion to provide more patients with greater access to treatment...


28 Oct, 2014, 15:43 GMT CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device

CSL Behring announced today that its affiliate company, CSL Behring AG, of Bern, Switzerland and Enable Injections, LLC, of Franklin, Ohio have...


12 May, 2014, 00:15 BST New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP)

Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an...


02 May, 2014, 14:49 BST CSL Behring recluta a su primer paciente en el ensayo pivote en fase III del factor recombinante VIII de cadena única

CSL Behring anunció hoy que se ha reclutado al primer paciente dentro el ensayo pivote pediátrico en fase III que evalúa la eficacia, seguridad y...


03 Apr, 2013, 13:00 BST CSL Behring Donates Medicine Used in Treating Bleeding Disorders to World Federation of Hemophilia

As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation ...


14 Jan, 2013, 14:00 GMT CSL Behring Seeks Proposals for the Third Annual Interlaken Leadership Awards

Committed to improving the quality of life for people with rare and serious diseases, CSL Behring is calling for proposals for the 2013 Interlaken...


31 May, 2011, 15:00 BST CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant ...


21 Apr, 2011, 15:00 BST CSL Behring Receives European Commission Marketing Authorization for Hizentra(R), the first 20 Percent Subcutaneous Human Immunoglobulin for Treatment of Primary and Secondary Immunodeficiencies

CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra(R) (Human Normal Immunoglobulin), 20...


28 Feb, 2011, 08:00 GMT Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority

- Experts on rare disease from the medical, scientific and patient advocacy communities examine critical issues and solutions in Paris and Bethesda...